Structure Therapeutics Inc.
Structure Therapeutics Inc. (GPCR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gpcr · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Structure Therapeutics Inc. (GPCR) measures how much investors pay for each dollar of the company's trailing earnings. GPCR's current PE ratio of N/A is calculated by dividing its stock price of $36.86 by its TTM earnings per share of -$2.35.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2020 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Structure Therapeutics Inc.You GPCR | $2.1B | N/A | — | -$2.35 |
 AbCellera Biologics Inc. ABCL | $1.7B | N/A | — | -$0.49 |
 Celldex Therapeutics, Inc. CLDX | $1.9B | N/A | — | -$3.89 |
 Edgewise Therapeutics, Inc. EWTX | $3.7B | N/A | — | -$1.63 |
 Galapagos N.V. GLPG | $1.8B | 5.74x | — | $4.85 |
 Liquidia Corporation LQDA | $5.7B | N/A | — | -$0.80 |
 Mesoblast Limited MESO | $1.8B | N/A | — | -$0.85 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.39 | — | |
2024-12-31 FY2024 | — | $-2.33 | — | |
2023-12-31 FY2023 | — | $-2.44 | — | |
2022-12-31 FY2022 | — | $-1.40 | — | |
2021-12-31 FY2021 | — | $-1.09 | — | |
2020-12-31 FY2020 | — | $-0.43 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Structure Therapeutics Inc. (GPCR) measures how much investors pay for each dollar of the company's trailing earnings. GPCR's current PE ratio of N/A is calculated by dividing its stock price of $36.86 by its TTM earnings per share of -$2.35.
Frequently asked questions
GPCR pe ratio · 6 questionsGPCR's current PE ratio is N/A as of 2026-06-08, based on a stock price of $36.86 and TTM EPS of -$2.35. Data sourced from Financial Modeling Prep via GPCR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Structure Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08